Trials / Completed
CompletedNCT01570504
Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 312 (actual)
- Sponsor
- Centro per le Malattie Tropicali · Academic / Other
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite. Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin | oral formulation |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2018-06-08
- Completion
- 2018-06-08
- First posted
- 2012-04-04
- Last updated
- 2018-06-14
Locations
9 sites across 3 countries: Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01570504. Inclusion in this directory is not an endorsement.